OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Infectious Diseases is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Adaora “Ada” Alise Adimora	1502
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	1151
Highlights from the sixth ESCMID Conference on Vaccines	1012
DNDi receives Dutch funding boost	556
HIV vaccine trial failure	539
Research in brief	417
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	413
Research in brief	411
COVID-19 vaccination protects children and adolescents	364
A patient with secondary syphilis following incomplete treatment of primary infection	361
Environment and infectious diseases	340
Promoting diversity and equity in publishing	304
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children	287
A step forward in the journey towards hookworm vaccines	282
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	276
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7	264
Listeria monocytogenes: a rare, deadly cause of peritonitis	252
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	252
GoGoVax dispels hopes for gonorrhoea vaccination	248
Updated criteria for paediatric sepsis and septic shock	243
Correction to Lancet Infect Dis 2025; 25: e280–93	237
Infectious disease surveillance update	230
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	229
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	222
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	222

Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1	219
The superiority of bivalent over monovalent booster vaccines	214
Attention to skin-related neglected tropical diseases	209
The lasting lessons of mpox: infection, vaccination, and immune memory	209
Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer	209
Shaping opportunities for future clinical trials in tuberculosis	205
Ivan Hirsch	200
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden	189
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	182
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	181
The next chapter for Africa's genomic initiatives	175
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	172
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom	172
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	165
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis	164
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria	164
Measles immunity gaps and outbreak risk in a shifting landscape	163
Mpox in people with past infection or a complete vaccination course: a global case series	154
Best practice guidelines for viral hepatitis service delivery in prisons	154
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial	151
Kyasanur Forest disease: an emerging arboviral threat	149
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect	146
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	145
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco	144
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review	144
Surge of cutaneous leishmaniasis in Pakistan	143
Reflecting on lessons from the 2014–16 Ebola virus outbreak	141
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study	141
Threat of HIV and tuberculosis drug resistance after US funding cuts	141
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	140
Research in brief	139
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	139
Research in brief	138
A new monoclonal in the arMAMentarium against malaria	137
New flavours of tuberculosis treatment for children	137
Twin threats: climate change and zoonoses	136
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?	136
Global cholera resurgence—a preventable tragedy	135
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site	135
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents	135
WHO's first global infection prevention and control report	134
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia	133
When mpox is not mpox: varicella and measles in DR Congo	132
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study	132
Is combination antiviral therapy for influenza the optimal approach?	130
Addressing the shortage of cholera vaccines	127
The implications of mpox breakthrough infections on future vaccination strategies	122
Theresa Ochoa—staying on top of infectious diseases in Peru	121
Research in brief	118
RSV prevention: public health lessons from the southern hemisphere	117

Full-dose NSAIDs at the first sign of respiratory infection?	115
Tuberculosis recovery in Georgia: implementing more by 24	113
Emil Gotschlich	113
Severe influenza: is there a role for antiviral combinations?	113
Election of Regional Director for the Western Pacific	113
Supporting healthcare access for refugees and migrants	111
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world	110
Interplay of infection and vaccination in long-term protection from COVID-19	110
Serpiginous-like choroiditis in ocular tuberculosis	109
COVID-19 mortality in Africa and Asia – Authors' reply	104
Infectious disease surveillance update	104
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa	104
High-dose primaquine reduces vivax relapses: time for change	103
Elisabeth Presterl—always looking forward	103
Research in brief	102
Immune evasiveness of SARS-CoV-2 variants and vaccine selection	100
The response of mpox-associated inflammatory syndrome to steroid therapy	100
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis	98
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0	97
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2	97
Correction to Lancet Infect Dis 2023; 23: e469	97
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5	96
Correction to Lancet Infect Dis 2025; 25: e622	94
Correction to Lancet Infect Dis 2025; 25: e47–58	94
Vaccine and surveillance implications of dengue underdetection	94
Malaria vaccine development in Mali: a step towards transmission-blocking strategies	93
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis	93
WHO Pathogen X conference	93
The global burden of cryptococcosis—a neglected tropical disease?	92
Curing chronic hepatitis B virus infection	89
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention	88
WHO publishes update on global antibiotic resistance	86
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study	86
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant	86
Patient-centred approaches for drug-resistant tuberculosis	85
Post-viral sequelae of COVID-19 and influenza	84
What can be learnt from the world's first national vaccination programme against gonorrhoea	84
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply	84
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	82
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	81
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study	80
Correction to Lancet Infect Dis 2026; published online March 23. https://doi.org/10.1016/S1473-3099(26)00058-7	80
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86	79
Super-spreaders: a historical review	79
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe	78
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	78
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis	78
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	78
Lessons learnt from conducting a randomised clinical trial in eumycetoma	77
Spreading awareness on lymphatic filariasis	77
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines	77
Infectious disease surveillance update	77
A step closer to elimination of meningococcal disease	77
Advancing integration: progress reported for skin NTDs	76
Outbreaks compound Brazil's flooding disaster	75
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply	75
Re-emergence of Oropouche virus in Brazil and Latin America	75
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials	74
Pui-Ying Iroh Tam	72
Vaccine pragmatism in the 21st century	72
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil	71
Highlights from ECCMID 2022	71
Amal Saif Al-Maani—fighting antimicrobial resistance	71
The urgent need to scale-up fungal diagnostics in Africa	71
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices	70
Is the end of gonorrhoea in sight?	70
Sir Michael Anthony Epstein	70
On the frontline during the COVID-19 pandemic	70
Child-friendly rifapentine formulation is a game changer	69
Imprinted hybrid immunity against XBB reinfection	69
Research in brief	69
Moxidectin versus ivermectin for strongyloidiasis control	69
Social workers and neglected tropical diseases	69
Unexpected finding in a 17-year-old female undergoing screening colonoscopy	68
Next-generation malaria subunit vaccines to reduce disease burden in African children	68
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7	67
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial	67
A tale of potential mpox reinfection	67
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluste	66
Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch	66

A rare case of rabies-like Australian bat lyssavirus infection	65
Correction to Lancet Infect Dis 2023; 23: e259–65	65
Gender and geographical representation at infectious diseases and clinical microbiology conferences	65
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study	64
Sleeping sickness: time for dreaming	64
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4	64
Human ocular thelaziosis—a zoonosis of the eye	62
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa	62
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	62
COVID-19 mortality in Africa and Asia	62
Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial	61
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial	61
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features	61
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	60
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	60
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	60
doxyPEP: a controversial new tool against STIs	60
DoxyPEP: thinking towards implementation	60
Incidence and risk factors of tuberculosis among 420 854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004–18): a cohort study	60
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3	60
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution:	60
Bangladesh launches measles vaccine drive amid outbreak	59
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study	59
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	59
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	58
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	58
Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial	58
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis	58
Understanding the immunogenicity of RTS,S in infants	57
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster	57
Randomised controlled trials for mpox in endemic countries	56
A step forward for Plasmodium falciparum malaria transmission-blocking vaccines	56
A shared history	56
Lyda Osorio—tackling South America's infectious diseases	55
A vanquished threat or a cautionary tale?	55
Monkeypox trial to begin in DR Congo	55
Experts react to SAGO's preliminary report	55
Lien Jih-ching	55
Learning and confirming in publicly funded antiviral trials	55
Deaths of unknown cause in DR Congo	54
Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths	54
COVID-19 versus influenza: the need to align policies with COVID-19 realities	54
Azithromycin mass drug administration: balancing survival benefits and risks in children	54
Antibody durability at 1 year after Sputnik V vaccination	54
Antiblackness in the Ebola response in Sierra Leone	54
Global measles cases up 20% in 2023	54
Developing the EAVE III platform for future health crises	52
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions	52
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	52
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic	52
Hospital admissions for group A streptococcal infections in England: current rates and historical perspective	52
The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus	52
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	52
Correction to Lancet Infect Dis 2023; 23: 789	51
Correction to Lancet Infect Dis 2025; 25: e11–12	51
Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4	51
Correction to Lancet Infect Dis 2025; 25: 764–74	51
Humanitarian crisis in Tigray amidst civil war	50
Mpox control strategies: using behaviour change to complement, not replace, vaccination	50
Successful use of interferon alfa-2a for persistent parvovirus B19 infection	50
Salmonella Typhimurium outbreak linked to chocolate	50
Correction to Lancet Infect Dis 2025; published online Oct 29. https://doi.org/10.1016/S1473-3099(25)00466-9	50
Candida albicans fungal ball in the eyeball	50
Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry	49
A new key-player for onchocerciasis elimination	49
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomi	49
A new formulation of praziquantel to achieve schistosomiasis elimination	49
Revisiting oral antivirals for COVID-19 in the hospital setting	49
A combined ELISA for infection-induced and vaccine-induced mpox antibodies during the clade Ib outbreak in Rwanda: an observational, cross-sectional, clinical validation study	49
Na-GST-1 adsorbed on Alhydrogel co-administered with different Toll-like receptor agonists in hookworm-naive adults using a controlled human infection model in the USA: a phase 2, double-blind, random	48
H5N1 avian influenza: tracking outbreaks with real-time epidemiological data	48
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia	47
Correction to Lancet Infect Dis 2025; published online Feb 13. https://doi.org/10.1016/S1473-3099(24)00749-7	47
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prosp	47
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-base	46
Measuring population immunity against influenza using individual antibody titres: a multicountry, retrospective observational study	46
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African c	46
Sense and susceptibility: predicting influenza dynamics from immune landscapes	46
Artificial intelligence to transform public health in Africa	45
Struggling with a new dengue epidemic in Nepal	45
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation	45
Highlights from ASTMH 2024	44
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis	44
What is the pandemic potential of avian influenza A(H5N1)?	44
Limited progress towards immunisation targets in 2023	44
GLASS report on antibiotic use data for 2022	43
Ana Gligić	43
Navigating treatment duration in osteoarticular Candida infections – Authors' reply	43
Mallika Imwong—championing malaria genomics	43
Correction to Lancet Infect Dis 2022; published online May 17. https://doi.org/10.1016/S1473-3099(22)00149-9	42
Infectious diseases in the COVID-19 era: gaps between countries	42
Correction to Lancet Infect Dis 2022; published online March 8. https://doi.org/10.1016/S1473-3099(21)00692-7	42
Seasonal variation in azithromycin prescription	42
Real-world use of nirmatrelvir–ritonavir: who benefits?	42
Correction to Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4	42